Biotech: Page 90
-
Getty / Edited by BioPharma Dive
Sarepta tries to fine-tune its gene therapy approach
Research deals with Codiak Biosciences and Selecta Biosciences could help Sarepta work around a key challenge in gene therapy development.
By Jacob Bell • June 22, 2020 -
In big year for microbiome drugs, a small biotech sets the bar
Data from Finch Therapeutics will likely be held up against two rivals planning to present their own clinical results later this year.
By Jacob Bell • June 19, 2020 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Biogen loses patent dispute with Mylan, putting its top drug's future in doubt
Despite an upcoming appeal from Biogen, Mylan wants to launch its copycat drug as soon as possible and says it's working with the FDA to bump up the Nov. 16 target approval date.
By Ben Fidler • Updated June 18, 2020 -
AbbVie puts $60M into ex-Dendreon CEO's company in autoimmune drug pact
The deal gives AbbVie an option to license a drug Alpine Immune Sciences — a company run by one-time Dendreon CEO Mitch Gold — is developing for autoimmune diseases.
By Ben Fidler • June 18, 2020 -
Neurocrine bets $2B on Takeda's psychiatry drugs
The deal provides Neurocrine with three clinical-stage drugs and a more diversified pipeline, while Takeda gets more bandwidth to work on its other neuroscience projects.
By Jacob Bell • June 16, 2020 -
Getty / Edited by BioPharma Dive
Magenta's technology attracts another gene therapy developer
A freshly inked research pact will test one of biotech's antibody drug conjugates as a conditioning treatment for patients receiving Beam Therapeutics' gene editing therapies.
By Jacob Bell • June 15, 2020 -
Kendall Davis / BioPharma Dive/BioPharma Dive
CureVac gets German backing for coronavirus vaccine, but says it's independent
An investment of 300 million Euros gives the German government a 23% stake in CureVac, but won't grant the country exclusive national rights to a vaccine nearing human testing.
By Jonathan Gardner • June 15, 2020 -
Jonathan Gardner/BioPharma Dive
Agios, seeking a new strategy, touts positive data and marketing deal
The company has sold off royalty rights to one of its drugs amid a push to focus on a wholly owned medicine it's developing for several blood diseases.
By Jacob Bell • June 12, 2020 -
AstraZeneca spinout wins first FDA approval 2 years after launch
Viela Bio can now call itself a commercial-stage company, but its new drug Uplizna will compete with existing therapies in the rare neurological disease it just got approved to treat.
By Jonathan Gardner • June 12, 2020 -
Moderna to start in July what could be first late-stage coronavirus vaccine trial
The Phase 3 study, which would be run in collaboration with the NIH, is expected to enroll 30,000 participants in the U.S. Other similarly large studies of candidates from AstraZeneca and J&J could quickly follow.
By Ben Fidler • June 11, 2020 -
Regeneron brings first COVID-19 antibody 'cocktail' into human tests
The biotech has begun a pair of clinical trials testing a two-drug combination in COVID-19 patients. Two other studies, starting later this month, aim to prove the therapy can prevent coronavirus infections.
By Ben Fidler • June 11, 2020 -
Courtesy of Genmab A/S
AbbVie hands Genmab $750M in latest bid to grow cancer drug business
Best known for Humira, AbbVie has made a concerted effort to build its cancer drugs business, with mixed results. The Genmab alliance could take the Illinois drugmaker in a new direction.
By Ben Fidler • June 10, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Drug regulators in agreement on coronavirus vaccine trials, FDA official says
Health agencies will be under pressure to clear promising vaccines quickly. But Peter Marks, a top FDA official, said regulators will still want to see large trials to provide proof of safety.
By Jonathan Gardner , Ben Fidler • June 9, 2020 -
China's Innovent buys rights to Roche cancer technology
The deal covers research into cell therapies and bispecific antibodies, and grants Roche an option to develop any resulting product outside of China.
By Jonathan Gardner • June 9, 2020 -
Lundbeck to cut more than 100 jobs as it remodels R&D
The roughly 130 to 160 positions are in R&D and R&D-related functions, a company spokesperson confirmed, and the majority of them are in Lundbeck's Denmark offices.
By Jacob Bell • June 9, 2020 -
Alnylam details data for kidney disease drug under FDA review
Treatment with lumasiran significantly lowered levels of a key chemical correlated with kidney failure, paving the way for what would be Alnylam's third drug approval.
By Jonathan Gardner • June 8, 2020 -
Getty / Edited by BioPharma Dive
Sarepta, with new data, plans final push for limb-girdle gene therapy
New results show a higher dose of Sarepta's gene therapy outperformed a lower one, a finding its CEO believes should build confidence in several of its other experimental treatments.
By Ben Fidler • June 8, 2020 -
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
The China-based cell therapy developer, whose myeloma therapy is a rival to one from Bristol Myers and Bluebird, outraised this year's previous top initial biotech stock offering.
By Ben Fidler • June 5, 2020 -
Amid a pandemic, Atlas becomes latest venture firm to raise cash for drug startups
Atlas Venture started its 12th fund in March. By early June it had received more than $1 billion in demand, mostly from returning limited partners.
By Jacob Bell • June 5, 2020 -
Jacob Bell/BioPharma Dive
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA
The deal follows similar pacts involving Merck, Biogen, Roche and others, reflecting growing interest by pharmaceutical companies in the emerging field.
By Ben Fidler • June 4, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
COVID-19 studies of malaria, blood pressure pills come under scrutiny
The Lancet and The New England Journal of Medicine issued "statements of concern" regarding two high-profile trials they published, citing gaps in a database used by the authors.
By Jonathan Gardner • Updated June 4, 2020 -
Biotech IPOs near last year's pace, despite COVID-19 pandemic
A successful IPO from Pliant Therapeutics is the first of five potential offerings by biotechs this week, suggesting activity is picking up following earlier coronavirus-related disruption.
By Ben Fidler • June 3, 2020 -
Courtesy of Regeneron Pharmaceuticals
Regeneron expands Intellia gene editing deal as its post-Sanofi future emerges
Regeneron and Intellia will grow their alliance and work on hemophilia, an already competitive space that includes several experimental gene therapies.
By Jonathan Gardner • June 1, 2020 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
Details lacking, but new remdesivir data point to a benefit for 'moderate' COVID-19 patients
The results suggest that Gilead's drug may help a broader swath of patients with coronavirus disease, though the magnitude of benefit is unclear.
By Jacob Bell • June 1, 2020 -
Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
Tauvid, which identifies the size and spread of tau protein clusters in the brain, could help Alzheimer's researchers as they shift away from a long-dominant focus on amyloid beta.
By Jacob Bell • May 29, 2020
Previous
